FA
RVLP

Forefront Analytics’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Forefront Analytics’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,118
Closed -$99K – 70
2021
Q1 		$99K Buy
30,118
+12,027
+66% +$49.5K 0.04% 63
2020
Q4 		$72K Sell
18,091
-2,564
-12% -$14.8K 0.03% 60
2020
Q3 		$111K Buy
+20,655
New +$119K 0.05% 54

Other funds holding RVLP

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
RA
Rovida Advisors Fort Lauderdale, Florida $116M AUM 12.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Forefront Analytics's RVLP Position: Q2 2021 in Review

Forefront Analytics sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q2 2021, closing a stake of 30,118 shares — an estimated $99K sold.

Forefront Analytics first reported a position in RVLP in Q3 2020 and held it in 3 quarters. The position peaked at $111K in Q3 2020. 46 funds tracked by Wall St. Rank hold RVLP as of Q2 2021.

  • Forefront Analytics reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q2 2021 after selling out during the quarter.
  • Forefront Analytics sold 30,118 RVL Pharmaceuticals plc Ordinary Shares shares in Q2 2021, an estimated $99K.
  • Forefront Analytics first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q3 2020 and held it in 3 quarters.
  • Forefront Analytics's RVL Pharmaceuticals plc Ordinary Shares position peaked at $111K in Q3 2020.
  • 46 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q2 2021.

Based on Forefront Analytics's 13F filing for Q2 2021, filed 10 Aug 2021.